Drug Trial Radar · NCT06722417
A Single Dose Study to Assess Adverse Events and How Oral Icalcaprant Moves Through the Body in Healthy Adult Japanese and Han Chinese Participants
Last checked: Nov 19, 2026Latest source record: Jan 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
16
Actual
Start
Nov 26, 2024
Primary completion
Jan 17, 2025
Study completion Jan 17, 2025
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Dec 9, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study will assess the pharmacokinetics, safety, and tolerability of icalcaprant administered orally in healthy adult Japanese and Han Chinese participants.
Conditions
- Healthy Volunteer
Interventions
IcalcaprantDrug
Oral capsules
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Observed Plasma Concentration (Cmax) of IcalcaprantTime frame: Up to approximately 6 days
- Time to Cmax (Tmax) of IcalcaprantTime frame: Up to approximately 6 days
- Terminal Phase Elimination Rate Constant (Beta) of IcalcaprantTime frame: Up to approximately 6 days
- Terminal Phase Elimination Half-Life (t1/2) of IcalcaprantTime frame: Up to approximately 6 days
- Area under the plasma concentration-time curve from time 0 until the last measurable Concentration (AUCt) of IcalcaprantTime frame: Up to approximately 6 days
- Area under the plasma concentration-time curve from time 0 to infinity (AUCinf) of IcalcaprantTime frame: Up to approximately 6 days
- Number of Participants with Adverse Events (AEs)Time frame: Up to approximately 37 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Anaheim Clinical Trials, LLC /ID# 271323
Anaheim, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.